$0.68
4.41%
Downside
Day's Volatility :5.8%
Upside
1.45%
4.41%
Downside
52 Weeks Volatility :69.27%
Upside
67.85%
Period | Cyclo Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -46.03% | 0.0% |
6 Months | -58.02% | 0.0% |
1 Year | -57.37% | 0.0% |
3 Years | -90.66% | -22.3% |
Market Capitalization | 19.5M |
Book Value | - $0.18 |
Earnings Per Share (EPS) | -0.82 |
Wall Street Target Price | 0.95 |
Profit Margin | 0.0% |
Operating Margin TTM | -4577.99% |
Return On Assets TTM | -282.49% |
Return On Equity TTM | -22663.91% |
Revenue TTM | 1.1M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 5.1% |
Gross Profit TTM | 1.2M |
EBITDA | -21.1M |
Diluted Eps TTM | -0.82 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | -0.66 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.16 |
What analysts predicted
Upside of 39.71%
Sell
Neutral
Buy
Cyclo Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cyclo Therapeutics Inc | -41.38% | -58.02% | -57.37% | -90.66% | -83.81% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cyclo Therapeutics Inc | NA | NA | NA | -0.67 | -226.64 | -2.82 | NA | -0.18 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cyclo Therapeutics Inc | Buy | $19.5M | -83.81% | NA | 0.0% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Cyclo Therapeutics Inc
Revenue is down for the last 4 quarters, 495.47K → 123.10K (in $), with an average decrease of 37.1% per quarter
Netprofit is down for the last 2 quarters, -4.34M → -5.98M (in $), with an average decrease of 37.7% per quarter
In the last 1 year, Haleon Plc Spon Ads has given 28.5% return, outperforming this stock by 85.9%
EPIQ Capital Group, LLC
Founders Fund V Management, LLC
Vanguard Group Inc
Geode Capital Management, LLC
Founders Fund VI Management, LLC
BlackRock Inc
cyclodextrin technologies development, inc. (ctd), the "company", was organized as a florida corporation on august 9, 1990 with operations beginning july, 1992. in may of 1994 the company became a fully reporting public company listed on the otc bb under the symbol ctdi. in 2000, the company altered its corporate structure to a holding company with subsidiary companies. the otc bb symbol was changed to ctdh. ctd holdings, inc. (the "company") was originally formed to market and sell cyclodextrins and related products to the food, pharmaceutical, and other industries; it also provided consulting services related to cyclodextrin technology. ctdh, as a holding company, will acquire, create, and invest in companies that will develop, market, and/or sell products containing cyclodextrins. the company currently operates four wholly owned subsidiaries: ctd, inc.; nanosonic products, inc.; sphingo biotech, inc.; and ferrazo environmental technologies, inc.
Organization | Cyclo Therapeutics Inc |
Employees | 8 |
CEO | Mr. N. Scott Fine |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.68
-0.29%
Keyarch Acquisition Corp
$0.68
-0.29%
Connexa Sports Technologies Inc
$0.68
-0.29%
Us Value Etf
$0.68
-0.29%
First Wave Biopharma Inc
$0.68
-0.29%
Global X Msci Next Emerging
$0.68
-0.29%
Fat Projects Acquisition Corp
$0.68
-0.29%
Capital Link Global Fintech
$0.68
-0.29%
Applied Uv Inc
$0.68
-0.29%